Science

Bladder Cancer

Jan 29, 2025, 12:52

No survival benefit from NAC in bladder cancer

Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared an article by Cagri Akpinar et al. on X:

“Variant histology in bladder cancer poses a unique treatment challenge.

A study of 221 patients found NO survival benefit from NAC No significant differences in outcomes (OS: HR 1.88, p=0.14; CSS: HR 1.34, p=0.50; RFS: HR 1.13).

Use NAC cautiously in VH, as response may hinge on the % of urothelial component.”

The effect of neoadjuvant chemotherapy on survival outcomes inpatients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Uro-oncology Association.

Authors: Cagri Akpinar, et al.

No survival benefit from NAC in bladder cancer

bladder cancer Cagri Akpinar cancer Cleveland Clinic Urology fight against cancer Global fight against cancer neoadjuvant chemotherapy OncoDaily Oncology

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization